<$BlogRSDUrl$>

News, Links and Commentary

Wednesday, January 25, 2006

Lucentis Compares Well to Verteporfin PDT for Wet MD 

Genentech, Inc. have released positive results after the first year of their two-year Phase III trial of the wet MD drug Lucentis.

Data from the ANCHOR study comparing Lucentis to verteporfin (Visudyne(R)) photodynamic therapy (PDT) showed a difference in mean change in visual acuity of 18 letters for patients treated with 0.3 mg of Lucentis and 21 letters for patients treated with 0.5 mg of Lucentis from study entry compared to those treated with PDT at 12 months.

In the first year of this 2-year study, patients treated with Lucentis gained an average of 8.5 letters in the 0.3 mg dose group and 11 letters in the 0.5 mg dose group compared to patients treated with PDT, who lost an average of 9.5 letters.

'Preliminary Data Show Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration' (Genentech, Inc. media release at Doctor's Guide, 16 January 2006).

Note: Genentech also make Avastin, a drug that some eye specialists are currently using to treat MD despite it being approved only for the treatment of a particular cancer. Read more in a previous RetGen post, 'Wet MD - Lucentis vs Avastin' (28 September 2005).

Comments:
Thanks for the auspicious writeup. It in truth was once a leisure account it.
Glance complicated to far introduced agreeable from you!
By the way, how can we communicate?

My website :: Intercom sans fil
 
Post a Comment

This page is powered by Blogger. Isn't yours?